Marriage Counselors in Laurel, MS Accepting Medicare

4 Marriage Counselors found. Showing 1 - 4

Jeanine Boykin, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 33 Lake Heritage Rd, Laurel, MS 39443 Phone: 601-705-1901

Casey Keith, LMFTA Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1721 W 10th St, Laurel, MS 39440 Phone: 601-425-9322

Elise Bagley, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 15 Village Park Dr, Laurel, MS 39443 Phone: 601-705-1901

Mrs. Melissa Rae Cummings Alawine Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 265 Reid Rd, Laurel, MS 39443 Phone: 601-422-7786

News Archive

SEC declares CCBC's registration statement effective

China Cord Blood Corporation, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Securities and Exchange Commission ("SEC") declared the Company's registration statement effective on February 9, 2010. The registration statement relates to the ordinary shares underlying warrants and certain other securities issued in connection with the initial public offering of Pantheon China Acquisition Corp.

Otsuka Pharmaceutical acquires newly issued common shares of MethylGene

Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd. based in Japan, announces that on October 20, 2009, pursuant to the private placement disclosed on October 14, 2009, it acquired 3,686,182 newly issued common shares of MethylGene Inc. Following the closing of this private placement, Otsuka Pharmaceutical owns 9.12% of the issued and outstanding common shares of MethylGene.

UCSD's upcoming Patient Safety Conference to be held on Feb. 16

UC San Diego's upcoming Patient Safety Conference, "New Technologies to Patient Care: The Promise and the Peril" will be held Thursday, February 16, 8:00 a.m. to 4:30 p.m. at the Medical Education and Telemedicine Building located at 9500 Gilman Drive, La Jolla, CA 92093.

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

Read more Medical News

› Verified 9 days ago